NCT07777263|Not Yet RecruitingPhase 3
Loading search results
Sponsor study identifier
interventional
600
1 country
1
Study Start
October 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
October 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
October 2040
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
High-risk prostate cancer is usually treated with a combination of radiation therapy and hormone therapy (ADT). Radiation destroys cancer cells, while ADT lowers testosterone, a hormone that prostate cancer cells need to grow. Together, these treatments help control the cancer. ADT is usually given for 18 to 24 months, but it can cause side effects that may affect quality of life. Some people with high-risk prostate cancer may do just as well with a shorter course of ADT. This study will identify people who are most likely to benefit from shorter treatment using imaging scans and tumor tests. It will then evaluate whether a shorter course of ADT works as well as the standard treatment while reducing long-term side effects.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2040
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 22, 2026
Actual (reported)August 20, 2026
Actual (reported)October 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
October 2035
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
October 2040
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
5-year biochemical failure-free survival (bFFS)
Time from ADT initiation to time of first occurrence of biochemical failure (per Phoenix definition: PSA nadir + 2 ng/ml)
5 years
Metastasis-free survival
5-8 years
Overall survival
5-8 years
Prostate cancer-specific mortality
5-8 years
8-year biochemical failure-free survival (bFFS)
8 years
Toxicity - Acute
5 years
Zoladex is given for 12 months instead of 24
The purpose of the study is to identify a subset of patient that may benefit to have a shorter Zoladex treatment (12 months vs 24 months)
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
First Submitted
July 22, 2026
First Posted
August 20, 2026
Study Start
October 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
October 2035
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
October 2040
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
August 20, 2026
Record last verified: 2026-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: